Greater reductions in HbA1c (around 1.21.6% vs 0.8%) Up to 80% of patients achieved HbA1c below 7% (vs around one-third) More weight loss (6.37.3% vs 3.0%) Improvements in triglycerides, non-HDL cholesterol and systolic blood pressure Most importantly, orforglipron demonstrated superior glycaemic control compared with dapagliflozin
It acts simultaneously on glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors, producing significant reductions in body weight and improvements in glycaemic control
Huberman has also publicly discussed the difference between medications developed through regulated research and products obtained through questionable gray-market sources
Sclerostin (SOST) mRNA levels have been discovered to be lowered by GLP-1, which is known to inhibit the formation of new bone
Those researching Retatrutide in Australia may encounter technical product information and research-use specifications from specialist peptide suppliers such as Australia Peptide Sciences
Skipping the starting dose significantly increases the risk of severe gastrointestinal side effects